"Reimbursement will be a major milestone for Volition in the commercialization and licensing of Nu.Q® in the human cancer ...

Keith: John, tell us a little bit about Chainguard and what you’re going to be showing us on DEMO today. John: Definitely. Chainguard is about four years old. We are the safe source for open source.

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Rachel is a freelancer based in Echo Park, Los Angeles and has been writing and producing content for nearly two decades on subjects ranging from tech to fashion, health and lifestyle to entertainment ...

Frequently a precursor to stroke or heart failure, a heart condition known as atrial fibrillation, goes undetected until it has progressed to an advanced stage. But atrial fibrillation, which is ...